Pierre Fabre Laboratories and the EspeRare Foundation will receive the “EURORDIS Company Award for Patient Engagement 2024”. The award ceremony, a part of the EURORDIS Black Pearl Awards scheduled for February 20th2024 will take place in Brussels (Belgium), recognizing the exemplary efforts and long-standing collaboration they have established with the Patient groups in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED).
EspeRare and Pierre Fabre, combined their complementary expertise in 2020 to jointly develop a groundbreaking prenatal therapy for XLHED patients, with the hope of delivering the first treatment to address this genetic condition before birth. Their shared commitment, values, and principles not only drive the development of this pioneering treatment but also empower the rare disease community to actively participate and contribute their insights at every stage of the drug development process. EspeRare and Pierre Fabre are genuinely honored and grateful to receive acknowledgement for their collaborative, patient-centric approach.
The inauguration day is even more remarkable as it takes place on the Ectodermal Dysplasias Awareness Day, a day that puts orphan disease community together to advocate about these rare conditions and the work being done. This makes Pierre Fabre and EspeRare extremely privileged to have a meaningful involvement with the patient community and collaboratively develop this potentially life-changing therapy being currently tested in the EDELIFE clinical trial.
For more information on the Eurordis Black Pearl Award please follow the link: Black Pearl Awards - Awardees - EURORDIS
